Portal Diabetes announced today that it received FDA breakthrough device designation for its implantable insulin pump system. The Westfield, Indiana–based company can now begin a Phase 1 study to evaluate its proprietary, temperature-stable insulin. It aims to deliver a functional cure for type 1 diabetes. Portal Diabetes developed its system, called the Portal Pump, to […]
Diabetes
Dexcom beats Street in Q4 on 13% sales growth
Dexcom (NSDQ:DXCM) shares ticked up after hours today on fourth-quarter results that came in ahead of the consensus forecast. Shares of DXCM rose 1% to $65.70 apiece in post-market trading today. The San Diego-based continuous glucose monitor (CGM) maker reported profits of $267.3 million. That equals 68¢ per share on sales of $1.259 billion for […]
Embecta names CEO Kurdikar as new board chair, picks new lead independent director
Embecta (Nasdaq:EMBC) announced today that its board of directors elected the company’s CEO, Devdatt “Dev” Kurdikar, as chair. The Parsippany, New Jersey-based BD Diabetes spinoff also named Dr. Claire Pomeroy as lead independent director. Both appointments go into effect immediately. These changes follow the retirement of David Melcher, who previously served as non-executive chair of the […]
LifeScan, i-SENS partner to launch CGM platform
LifeScan announced today that it partnered with i-SENS to launch a continuous glucose monitoring (CGM) system. Malvern, Pennsylvania–based LifeScan develops the OneTouch Bluetooth-connected blood glucose meter and mobile diabetes app. It aims to provide simplicity, accuracy and trust in diabetes management. i-SENS, a global in vitro diagnostics company, researches, develops and produces products leveraging advanced […]
Sava Technologies reports first clinical evidence for CGM biosensor
Sava Technologies today announced the first 10-day clinical evidence for its microsensor-based continuous glucose monitor (CGM). London-based Sava completed an independent clinical study of 46 participants with type 1 and insulin-dependent type 2 diabetes. The study took place across sites in Oxford and Cambridge, UK. It demonstrated reliable glucose measurement using Sava’s proprietary microsensor technology […]
MannKind enrolls first patient in study of inhaled insulin for pediatric type 1 diabetes
MannKind (Nasdaq:MNKD) announced today that it enrolled the first patient in the INHALE-1ST study of its Afrezza inhaled insulin. INHALE-1ST evaluates the initiation of Afrezza inhalation powder therapy shortly after type 1 diabetes diagnosis in pediatric patients. Afrezza (insulin human) inhalation powder is a fast-acting insulin formulation delivered through an inhaler device. MannKind engineered the mechanical […]
Trividia Health issues label correction for blood glucose monitors after death
Trividia Health announced today that it initiated a label correction for its True Metrix blood glucose monitoring systems. The label update affects True Metrix, True Metrix Air, True Metrix Go and True Metrix Pro blood glucose monitoring systems. Distribution regions include the U.S., UK, Mexico, Australia and the Caribbean. It requires a modification to the […]
Modular Medical hits validation milestone, targets commercial launch for insulin patch pump soon
Modular Medical (Nasdaq:MODD) announced that it started the production of validation lots for its Pivot tubeless insulin patch pump. The lots include the next-generation Pivot pump’s disposable cartridge and infusion set. With the milestone, the San Diego-based company said it remains on track for a commercial launch in the first quarter of 2026, subject to […]
Insulet launches Omnipod 5, Omnipod Discover in the Middle East
Insulet (Nasdaq:PODD) announced today that it launched its Omnipod 5 and Omnipod Discover offerings in the Middle East. The company made its automated insulin delivery system available in Saudi Arabia, Kuwait, Qatar and the United Arab Emirates (UAE). Omnipod 5 became the world’s first available tubeless, wearable, automated insulin delivery system when it received FDA […]
Embecta stock ticks up on Street-beating Q1
Embecta (Nasdaq:EMBC) shares got a boost today on first-quarter results that beat the consensus Wall Street forecast. Shares of EMBC rose 6.5% to $12.09 apiece in early-morning trading today. The Parsippany, New Jersey-based BD Diabetes spinoff reported profits of $44.1 million. That equals 74¢ per share on sales of $261.2 million for the three months ended […]
